Prostate-Specific Antigen: Any Successor in Sight?

摘要: Prostate cancer (PCa) is the most frequently diagnosed malignancy and second leading cause of death in men United States other parts world. The lifetime risk being with PCa approximately 16%. At present, only widely accepted screening tools for are prostate-specific antigen (PSA) digital rectal examination. PSA known to be prostate specific, but not hence lacks sensitivity detect a large number tumors, especially during early stages. level also affected by many factors, such as medication, inflammation (benign prostatic hyperplasia prostatitis), urologic manipulation; hence, controversy regarding appropriate serum that should trigger biopsy or have clinical relevance metastases. Attempts determine cells peripheral blood reverse transcriptase polymerase chain reaction did significantly improve diagnosis predict postoperative failure. Therefore, search continues novel biomarker panel markers well possible interventions use PSA. This article reviews several possibilities.